We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 31.13 | 4.24% | 766.10 | 766.99 | 736.00 | 738.04 | 3,397,607 | 01:00:00 |
From May 2019 to May 2024
LONDON--Hutchison China Meditech Limited (HCM.LN) on Wednesday announced that Hutchison MediPharma Limited, its majority owned drug R&D company, is set to receive $18 million in the second quarter from Eli Lilly & Co. (LLY).
The payments have been triggered by the positive result of the first proof-of-concept study of fruquintinib in the treatment of patients with metastatic colorectal cancer in China.
Fruquintinib, a novel selective inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, was discovered by Hutchison MediPharma Limited.
Shares closed Tuesday at 1,715 pence.
-Write to Jana Simmons at jana.simmons@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
